Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aldeyra TherapeuticsALDX 30 3-Year EPS without NRI Growth Rate is 19.20% as of Jun. 2026, which is 57% above its 10-year median of 12.20. GuruFocus rates ALDX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,162 Biotechnology companies, Aldeyra Therapeutics ranks better than 53.79% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 19.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 11.00% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 9.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Aldeyra Therapeutics was 27.60% per year. The lowest was -95.40% per year. And the median was 12.20% per year.
Aldeyra Therapeutics (NAS:ALDX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Aldeyra Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ALDX vs NTHI, BMEA, PTHS: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Aldeyra Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 19.20% mean?
Aldeyra Therapeutics (ALDX) has a 3-Year EPS without NRI Growth Rate of 19.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aldeyra Therapeutics and its competitors. This is 57% above median its historical median of 12.20. According to the industry distribution chart, Aldeyra Therapeutics ranks #537 out of 1162 companies in the Biotechnology industry, placing it in the top 46.2%.
Is Aldeyra Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Aldeyra Therapeutics' current 3-Year EPS without NRI Growth Rate of 19.20% is 57% above median its 10-year median of 12.20. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Aldeyra Therapeutics' value of 19.20% is 18.5% above this industry median. Based on the distribution chart, Aldeyra Therapeutics ranks #537 out of 1162 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' 3-Year EPS without NRI Growth Rate compare to NTHI and BMEA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #537 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This puts Aldeyra Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Aldeyra Therapeutics' value of 19.20% is 18.5% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 16.20, Aldeyra Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aldeyra Therapeutics's current 3-Year EPS without NRI Growth Rate of 19.20% is 18.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current 3-Year EPS without NRI Growth Rate is 19.20%, which is 57% above median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current 3-Year EPS without NRI Growth Rate of 19.20%. The current 3-Year EPS without NRI Growth Rate is 19.20%, which is 57% above median its 10-year median of 12.20 and 18.5% above the Biotechnology industry median of 16.20. Aldeyra Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current 3-Year EPS without NRI Growth Rate is 19.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
30GF Score
Get the complete analysis for ALDX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
